Medscape16h
New IL-7 Antagonist Lusvertikimab Shows UC Efficacy
In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
OSE’s UC therapy prompts 16% clinical remission after ten weeks
The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.
manilatimes2d
Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Using Cellectis' TALEN ® gene editing technology, we developed 'Smart CAR T cells' with the ability to express a ...
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...
manilatimes6d
Tyson Group Named to 2025 Training Industry Watchlist for Sales Training & Enablement
"The companies selected for our Sales Training and Enablement Watchlist are making a significant impact with innovative ...
pharmaphorum6d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...